{"id":10071,"date":"2026-03-23T08:22:10","date_gmt":"2026-03-23T13:22:10","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10071"},"modified":"2026-03-23T08:24:28","modified_gmt":"2026-03-23T13:24:28","slug":"nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/","title":{"rendered":"Nanoscope Therapeutics anuncia la publicaci\u00f3n de un nuevo estudio que destaca la evaluaci\u00f3n de la visi\u00f3n funcional en enfermedades de la retina."},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

DALLAS<\/span>,\u00a023 de marzo de 2026<\/span>\u00a0\u2014\u00a0Nanoscope Therapeutics, Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con el desarrollo y la comercializaci\u00f3n de terapias novedosas e independientes de la enfermedad para pacientes con p\u00e9rdida de fotorreceptores y discapacidad visual debido a la degeneraci\u00f3n retiniana, anunci\u00f3 hoy la publicaci\u00f3n de su \u00faltimo estudio observacional revisado por pares en una revista de Springer Nature,\u00a0Documenta Oftalmol\u00f3gica<\/i>, lo que contribuye a mejorar la comprensi\u00f3n del campo sobre c\u00f3mo medir mejoras significativas en la visi\u00f3n de pacientes con p\u00e9rdida visual grave en el mundo real.<\/p>\n

El estudio subraya la necesidad cr\u00edtica de realizar pruebas en pacientes que sufren p\u00e9rdida de visi\u00f3n debido a la p\u00e9rdida de las funciones de los bastones y los conos, destacando las herramientas que capturan con precisi\u00f3n las mejoras funcionales y la experiencia del paciente, y que pueden utilizarse en los flujos de trabajo est\u00e1ndar de retina.<\/p>\n

\u201cSi bien la agudeza visual mejor corregida (AVMC) ha sido durante mucho tiempo el est\u00e1ndar de oro en oftalmolog\u00eda, se puede complementar con nuevas formas de evaluar c\u00f3mo los pacientes con p\u00e9rdida grave de visi\u00f3n se desenvuelven en su vida diaria\u201d, dijo Samarendra Mohanty, Ph.D., autor principal y director cient\u00edfico de Nanoscope Therapeutics. \u201cMe enorgullece que nuestros hallazgos revisados por pares puedan ayudar a los m\u00e9dicos y a los m\u00e9dicos tratantes a tener confianza en el uso de estas pruebas para evaluar la visi\u00f3n funcional de sus pacientes\u2019.\u201d<\/p>\n

La publicaci\u00f3n destaca los hallazgos de un estudio prospectivo y observacional en 35 sujetos, 25 con p\u00e9rdida visual severa debido a retinosis pigmentaria (RP) y 10 con visi\u00f3n normal. Este estudio proporciona evidencia que respalda la fiabilidad y validez de la Prueba de Discriminaci\u00f3n de Formas Multiluminancia (MLSDT) como una evaluaci\u00f3n basada en el rendimiento de la capacidad visual en individuos con discapacidad visual severa. Adem\u00e1s de evaluar la agudeza visual corregida (BCVA) en el criterio de valoraci\u00f3n principal, el ensayo cl\u00ednico RESTORE Ph2b\/3 de la terapia principal de Nanoscope, MCO-010, evalu\u00f3 la visi\u00f3n funcional de los pacientes mediante MLSDT en un criterio de valoraci\u00f3n secundario. En la semana 52, la mayor\u00eda de los pacientes tratados con MCO-010 mejoraron en 2 o m\u00e1s niveles de luminancia en la MLSDT, una magnitud cl\u00ednicamente significativa. MCO-010 es la primera terapia que demuestra mejoras cl\u00ednicamente significativas y estad\u00edsticamente significativas en la visi\u00f3n de pacientes con RP que presentan p\u00e9rdida visual severa en un ensayo de registro aleatorizado, controlado con placebo.<\/p>\n

Samuel Barone, MD, director m\u00e9dico de Nanoscope Therapeutics, a\u00f1adi\u00f3: "Si bien Nanoscope contin\u00faa liderando el desarrollo de terapias optogen\u00e9ticas innovadoras, este estudio observacional demuestra nuestro compromiso de colaborar con la comunidad de especialistas en retina en la forma en que se mide el \u00e9xito terap\u00e9utico".\u201c<\/p>\n

Los resultados del estudio est\u00e1n disponibles en l\u00ednea en Springer Nature.\u00a0aqu\u00ed<\/a>.<\/p>\n

Acerca de la plataforma MCO
<\/b>MCO es una plataforma terap\u00e9utica intrav\u00edtrea de una sola aplicaci\u00f3n, ambulatoria y aplicable a cualquier enfermedad, dise\u00f1ada para restaurar la visi\u00f3n en pacientes con degeneraci\u00f3n de fotorreceptores, incluyendo retinosis pigmentaria (RP), enfermedad de Stargardt (ES) y atrofia geogr\u00e1fica (AG). Al activar las c\u00e9lulas bipolares de la retina, altamente densas, para que sean sensibles a la luz, MCO aprovecha el circuito visual restante tras la muerte de los fotorreceptores. El tratamiento con MCO no requiere pruebas gen\u00e9ticas, cirug\u00eda invasiva ni dosis repetidas, lo que permite una amplia aplicabilidad en pacientes dentro de los flujos de trabajo habituales en las consultas de retina.<\/p>\n

Acerca de Nanoscope Therapeutics
<\/b>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica restauradora de la visi\u00f3n, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b\/3 para la retinosis pigmentaria (RP) (NCT04945772<\/a>), se est\u00e1 llevando a cabo una presentaci\u00f3n continua de BLA a la FDA. Si se aprueba, MCO-010 tiene el potencial de convertirse en el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (NCT05417126<\/a>) y planea iniciar una\u00a0Ensayo de registro de fase 3<\/a>\u00a0en 2026. MCO-010 ha recibido las designaciones de V\u00eda R\u00e1pida y Medicamento Hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, y las designaciones de EMA de Medicamento Hu\u00e9rfano para cubrir distrofias dominantes de bastones y conos no sindr\u00f3micas y sindr\u00f3micas, as\u00ed como distrofias maculares. MCO-010 tambi\u00e9n ha recibido las designaciones de Sakigake (Pionero) y Medicamento Hu\u00e9rfano en Jap\u00f3n por parte del MHLW. Tambi\u00e9n se espera que un programa de Fase 2 para MCO en atrofia geogr\u00e1fica (GA) comience en 2026. Otros programas listos para IND incluyen la amaurosis cong\u00e9nita de Leber (LCA).<\/p>\n

Contacto:
<\/b>Nanoscope Therapeutics, Inc
(817) 857-1186
PR@nanostherapeutics.co<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0March 23, 2026\u00a0\u2014\u00a0Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced the publication of its latest peer-reviewed observational study in a Springer Nature journal,\u00a0Documenta Ophthalmologica, advancing the field\u2019s understanding of how to measure meaningful vision improvements […]<\/p>\n","protected":false},"author":1,"featured_media":10072,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10071","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-23T13:22:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-23T13:24:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease\",\"datePublished\":\"2026-03-23T13:22:10+00:00\",\"dateModified\":\"2026-03-23T13:24:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/\"},\"wordCount\":650,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MLSD-Publication_REV2.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/\",\"name\":\"Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MLSD-Publication_REV2.jpg\",\"datePublished\":\"2026-03-23T13:22:10+00:00\",\"dateModified\":\"2026-03-23T13:24:28+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MLSD-Publication_REV2.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_LI_MLSD-Publication_REV2.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/03\\\/23\\\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics anuncia la publicaci\u00f3n de un nuevo estudio que destaca la evaluaci\u00f3n de la visi\u00f3n funcional en enfermedades de la retina - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-03-23T13:22:10+00:00","article_modified_time":"2026-03-23T13:24:28+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Wilson PJ","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease","datePublished":"2026-03-23T13:22:10+00:00","dateModified":"2026-03-23T13:24:28+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/"},"wordCount":650,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MLSD-Publication_REV2.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/","url":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/","name":"Nanoscope Therapeutics anuncia la publicaci\u00f3n de un nuevo estudio que destaca la evaluaci\u00f3n de la visi\u00f3n funcional en enfermedades de la retina - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MLSD-Publication_REV2.jpg","datePublished":"2026-03-23T13:22:10+00:00","dateModified":"2026-03-23T13:24:28+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MLSD-Publication_REV2.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_LI_MLSD-Publication_REV2.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/03\/23\/nanoscope-therapeutics-announces-publication-of-new-study-highlighting-functional-vision-assessment-in-retinal-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Publication of New Study Highlighting Functional Vision Assessment in Retinal Disease"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"Wilson P.J."}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10071","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=10071"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10071\/revisions"}],"predecessor-version":[{"id":10076,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10071\/revisions\/10076"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/10072"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=10071"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=10071"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=10071"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}